• In early June 2026, GE HealthCare showcased an expanded nuclear medicine portfolio, featuring AI-enabled imaging workflows, PET and SPECT/CT systems, and radiopharmaceuticals such as Flyrcado, Vizamyl, DaTscan, and Cerianna to support more precise cardiology, neurology, and oncology care.
• A key theme was GE HealthCare’s Adaptive Theranostics model, which aims to link quantitative imaging, AI analytics, and connected workflows so clinicians can scale more personalized, data-driven treatment decisions across care settings.
• Next, we’ll examine how GE HealthCare’s push into AI-enabled Adaptive Theranostics could influence its investment narrative and future growth assumptions.

Find 47 companies with promising cash flow potential yet trading below their fair value.

GE HealthCare Technologies Investment Narrative Recap

To own GE HealthCare, you need to believe its imaging, AI and pharmaceutical diagnostics ecosystem can translate into steady earnings growth despite tariffs, China uncertainty and high debt. The new Adaptive Theranostics push strengthens the product narrative, but does not clearly change the key near term swing factors, which remain tariff impacts on margins and competitive pressure in imaging and radiopharmaceuticals.

Among recent announcements, the launch of Flyrcado in pharmaceutical diagnostics is most relevant, because it directly ties into GE HealthCare’s nuclear medicine and theranostics ambitions. As Flyrcado adoption builds alongside platforms like Omni Legend PET/CT and StarGuide SPECT/CT, the company’s ability to turn this portfolio into recurring, higher margin radiopharmaceutical revenue will be central to how much upside investors see in the current product cycle.

Yet against this opportunity, investors should also weigh the risk that rising competition in contrast agents and radiopharmaceuticals could pressure pricing and long term margins…

GE HealthCare Technologies’ narrative projects $24.0 billion revenue and $2.6 billion earnings by 2029.

Uncover how GE HealthCare Technologies' forecasts yield a $79.95 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about 4.1% annual revenue growth to roughly US$23.7 billion by 2029, so compared with the upside case for Flyrcado and theranostics, you can see how differently people view the same story and why it may be worth weighing several perspectives before deciding what this new nuclear medicine news could mean for you.

Explore 3 other fair value estimates on GE HealthCare Technologies - why the stock might be worth as much as 64% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free GE HealthCare Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.